FDA plays down cancer link with Sanofi’s Lantus
Shares of the French drugmaker, which have stumbled in the past week over Lantus concerns, rose 3.1 percent in Paris after the FDA also said patients should not stop taking their therapy without consulting a physician.
In a communication posted on its website, the agency questioned four recently published studies over the cancer [...]